Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 18Other hematologic neoplasm 14Plasma cell 12Thoracic 10Gastrointestinal 7Breast 7Head & Neck 6Genitourinary 5Myeloid 4Dermatologic 4Tumor-Agnostic 3Gynecologic 3CNS 3Other solid neoplasm 2Other 2Sarcoma 1Other neoplasm 1Endocrine 1

Conditions

Neurofibromatosis 1 1Melanoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Temozolomide 623Radiotherapy 411Bevacizumab 257Magnetic Resonance Spectroscopy 227Cyclophosphamide 179Radiosurgery 163Carboplatin 160Etoposide 132Radiation 129Vincristine 115Irinotecan 115Cisplatin 103Filgrastim 100Specimen Handling 90Nivolumab 88pembrolizumab 84Surgical Procedures, Operative 83Lomustine 83Topotecan 73Doxorubicin 61Melphalan 59Carmustine 57Radiotherapy, Intensity-Modulated 56sargramostim 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 51Chemotherapy, Adjuvant 51Blood Specimen Collection 51Erlotinib Hydrochloride 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Acetaminophen × CNS × Clear all
NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
192 enrolled 29 charts
CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

NCT04313374 2020-03-18

Integrated Pulmonary Index and Opioid Based Patient Controlled Analgesia

Istanbul University

Phase 4 Completed
90 enrolled
CNS

Brain Neoplasms

NCT03649165 2018-11-08

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

AstraZeneca

Phase 1 Completed
24 enrolled
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡